Actinium Pharmaceuticals Logo
US00507W2061
A2QA48
ATNM

Actinium Pharmaceuticals

Loading quotes...

Forecast

The analysts' average price target is €10.07 (+645.93%). The median is €4.50 (+233.33%).

Buy
  11
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Actinium shows strong preclinical efficacy of ATNM-400 in NSCLC models

    Actinium presented preclinical data on ATNM-400, an Actinium-225–linked radioconjugate for non‑small cell lung cancer, at the Society of Nuclear Medicine annual meeting. In KRAS‑mutant models, ATNM-400 as monotherapy outperformed the KRAS inhibitors sotorasib and adagrasib and enhanced their tumor‑cell killing when combined. In EGFR‑mutant models, ATNM-400 achieved 75% tumor growth inhibition versus 40% for osimertinib; the combination produced complete tumor regressions in all treated mice. The target antigen was detectable in approximately 98% of NSCLC tumors, and investor assessments see upside potential for the stock despite high cash burn. » More on de.investing.com


  • Actinium presents preclinical data on ATNM-400 and Actimab‑A at AACR on April 21

    Actinium will present posters with unpublished preclinical data on April 21 at the AACR annual meeting for ATNM-400 (an Ac‑225 radioconjugate for solid tumors) and Actimab‑A (a therapy for AML/MDS). ATNM-400 showed activity in models of metastatic, castration‑resistant prostate cancer as well as non‑small cell lung and breast cancer; Actimab‑A data illuminate a mechanism described as “transcriptional reprogramming.” The presentations are part of the session block “Radiopharmaceutical Platforms for Theranostic Precision Oncology”; Actimab‑A is being co‑developed with the National Cancer Institute. The stock is trading near its 52‑week low and the company reports high liquidity. » More on de.investing.com


  • Actinium Pharmaceuticals rises after promising preclinical data on ATNM-400

    Actinium Pharmaceuticals' stock rose about 3.7% after the presentation of new preclinical data on ATNM-400 at the San Antonio Breast Cancer Symposium 2025. The Actinium-225–based antibody‑radioconjugate showed strong antitumor activity in several breast cancer models, including hormone receptor‑positive, triple‑negative and treatment‑resistant tumors, with a favorable tolerability profile. The data demonstrated irreversible double‑strand DNA breaks caused by the alpha‑emitter payload; Actinium plans to advance ATNM-400 as a monotherapy and in combinations and sees potential also in prostate and non‑small‑cell lung cancer. » More on de.investing.com


  • Actinium: ATNM-400 shows efficacy in preclinical models of therapy-resistant breast cancer subtypes

    Actinium presents preclinical data demonstrating a tumor-inhibiting effect of ATNM-400 in hormone receptor–positive, HER2-positive and triple-negative breast cancer models that are resistant to tamoxifen or trastuzumab. In certain models, ATNM-400 produced tumor growth inhibition of more than 100% at higher doses. The Actinium-225 antibody–radioconjugate uses alpha particles, targets proteins that are overexpressed in association with resistance, and is designed to reduce the risk of unwanted lung toxicity. The data will be presented on December 11, 2025, at the San Antonio Breast Cancer Symposium; earlier preclinical results also showed promising effects in lung and prostate cancer. » More on de.investing.com


  • Actinium Pharmaceuticals: shareholders elect directors and ratify audit and compensation proposals

    At the 2025 annual meeting, Ajit S. Shetty and June S. Almenoff were re-elected as Class III directors until the 2028 annual meeting. Shareholders ratified CBIZ as the independent registered public accounting firm for fiscal year 2025 and approved, in a non-binding advisory vote, the named executive officer compensation. In addition, a three-year cycle was established for future advisory votes on executive compensation. A total of 15,494,573 common shares were represented; all proposals submitted to a vote were approved. » More on de.investing.com

Financials

In the last quarter, Actinium Pharmaceuticals had revenue of €30.67m and net profit of €24.45m
(EUR) June 2026
YoY
Revenue 30.67m -
Gross profit 30.67m -
Net profit 24.45m 518.94%
EBITDA 24.66m 535.48%

Fundamentals

Metric Value
Market capitalization
€46.9m
Number of shares
31.44m
52-week high/low
€1.56 - €0.67
Dividends No
Beta
0.02
P/E ratio
4.56
PEG ratio
0.02
P/B ratio
1.70
P/S ratio
1.47

Company profile

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Name
Actinium Pharmaceuticals
CEO
Sandesh C. Seth
Headquarters New York City, ny
USA
Website
Industry
Chemicals
IPO
27/12/2012
Employees 27

Ticker symbols

Exchange Symbol
AMEX
ATNM
Frankfurt
7AY1.F
DĂŒsseldorf
7AY1.DU
đŸȘ

Parqet  uses cookies. Learn more